» Articles » PMID: 28214253

Long Noncoding RNA LINC00673 Is Activated by SP1 and Exerts Oncogenic Properties by Interacting with LSD1 and EZH2 in Gastric Cancer

Overview
Journal Mol Ther
Publisher Cell Press
Date 2017 Feb 19
PMID 28214253
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

Long noncoding RNAs (lncRNAs) have emerged as important regulators in a variety of human diseases, including cancers. However, the biological function of these molecules and the mechanisms responsible for their alteration in gastric cancer (GC) are not fully understood. In this study, we found that lncRNA LINC00673 is significantly upregulated in gastric cancer. Knockdown of LINC00673 inhibited cell proliferation and invasion and induced cell apoptosis, whereas LINC00673 overexpression had the opposite effect. Online transcription factor binding site prediction analysis showed that there are SP1 binding sites in the LINC00673 promoter region. Next, luciferase reporter and chromatin immunoprecipitation (ChIP) assays provided evidence that SP1 could bind directly to the LINC00673 promoter region and activate its transcription. Moreover, mechanistic investigation showed that CADM4, KLF2, and LATS2 might be the underlying targets of LINC00673 in GC cells, and RNA immunoprecipitation, RNA pull-down, and ChIP assays showed that LINC00673 can interact with EZH2 and LSD1, thereby repressing KLF2 and LATS2 expression. Taken together, these findings show that SP1-activated LINC00673 exerts an oncogenic function that promotes GC development and progression, at least in part, by functioning as a scaffold for LSD1 and EZH2 and repressing KLF2 and LATS2 expression.

Citing Articles

The multifaceted role of post-translational modifications of LSD1 in cellular processes and disease pathogenesis.

Li Y, Wang B, Zheng Y, Kang H, He A, Zhao L Genes Dis. 2025; 12(3):101307.

PMID: 40028036 PMC: 11870172. DOI: 10.1016/j.gendis.2024.101307.


Discovery of novel dual-target inhibitors of LSD1/EGFR for non-small cell lung cancer therapy.

Wei Y, Sun M, Zhang R, Wang L, Yang L, Shan C Acta Pharmacol Sin. 2025; .

PMID: 39753983 DOI: 10.1038/s41401-024-01439-w.


LncRNAs orchestration of gastric cancer - particular emphasis on the etiology, diagnosis, and treatment resistance.

Elimam H, Moussa R, Radwan A, Hatawsh A, Elfar N, Alhamshry N Funct Integr Genomics. 2024; 24(5):175.

PMID: 39325107 DOI: 10.1007/s10142-024-01450-8.


Linc00673-V3 positively regulates autophagy by promoting Smad3-mediated transcription in NSCLC.

Ni H, Tang S, Lu G, Niu Y, Xu J, Zhang H Life Sci Alliance. 2024; 7(6).

PMID: 38527804 PMC: 10963591. DOI: 10.26508/lsa.202302408.


USP15 Represses Hepatocellular Carcinoma Progression by Regulation of Pathways of Cell Proliferation and Cell Migration: A System Biology Analysis.

Ren Y, Song Z, Rieser J, Ackermann J, Koch I, Lv X Cancers (Basel). 2023; 15(5).

PMID: 36900163 PMC: 10000201. DOI: 10.3390/cancers15051371.


References
1.
Zhang E, Kong R, Yin D, You L, Sun M, Han L . Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget. 2014; 5(8):2276-92. PMC: 4039162. DOI: 10.18632/oncotarget.1902. View

2.
Shi X, Ma C, Zhu Q, Yuan D, Sun M, Gu X . Upregulation of long intergenic noncoding RNA 00673 promotes tumor proliferation via LSD1 interaction and repression of NCALD in non-small-cell lung cancer. Oncotarget. 2016; 7(18):25558-75. PMC: 5041926. DOI: 10.18632/oncotarget.8338. View

3.
Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao S . Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell. 2015; 28(4):529-540. PMC: 4777353. DOI: 10.1016/j.ccell.2015.09.006. View

4.
Shi X, Sun M, Liu H, Yao Y, Song Y . Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013; 339(2):159-66. DOI: 10.1016/j.canlet.2013.06.013. View

5.
Nie F, Yu X, Huang M, Wang Y, Xie M, Ma H . Long noncoding RNA ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing KLF2 and NKD2 expression. Oncotarget. 2016; 8(24):38227-38238. PMC: 5503528. DOI: 10.18632/oncotarget.9611. View